Last updated on August 2018

LUME BioNIS: a Biomarker Study in Patients With NSCLC


Brief description of study

At present there are no approved predictive tumour- or serum-derived biomarkers guiding usage of anti-angiogenic therapies in patients with adenocarcinoma of NSCLC.The objective of this NIS is to examine whether genetic/genomic markers (alone or combined with clinical covariates) could be used to predict OS in NSCLC patients eligible for treatment with Vargatef. The investigations in this study are exploratory in nature and considered to be hypothesis generating. The results from these investigations may help to expand our understanding of the disease and the response to Vargatef.

Detailed Study Description

Purpose

Clinical Study Identifier: NCT02671422

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

Gesundheit Nord gGmbH | Klinikverbund Bremen
Bremen, Germany
7.22miles
  Connect »